Title

Presentation

Operator: Good afternoon, ladies and gentlemen, and welcome to the Alector Second Quarter and Midyear 2024 Earnings Conference Call. At this time, all participants are in listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. [Operator Instructions] As a reminder, this conference call is being recorded. I would now like to turn the call over to Katie Hogan, Senior Director of Corporate Communications and Investor Relations. Please go ahead.

Katie Hogan: Thank you, operator, and hello, everyone. Earlier this afternoon, we released our financial results for the second quarter 2024. The press release is available on our website at www.alector.com, and our 10-Q was filed with the Securities and Exchange Commission this afternoon. Joining me on the call today are Dr. Arnon Rosenthal, Co-Founder and CEO; Dr. Sara Kenkare-Mitra, President and Head of Research and Development; Dr. Gary Romano, Chief Medical Officer; and Dr. Marc Grasso, Chief Financial Officer. After our formal remarks, we’ll open the call for Q&A. I’d like to note that during this call, we’ll be making a number of forward-looking statements. Please take a moment to review our slide on the webcast, which contains our forward-looking statement disclosure and we also encourage you to review our SEC filings for more information. I would now like to turn the call over to Arnon Rosenthal, Chief Executive Officer. Arnon?

Arnon Rosenthal: Thank you, Katie. Good afternoon, everyone. We appreciate you joining our conference call today. I’ll start by highlighting Alector’s key initiatives during the first half of 2024. Then I’ll invite Gary to discuss our later stage clinical programs. Next, Sara will share the progress we believe we have achieved with Alector Brain Carrier, our proprietary versatile blood-brain barrier technology platform. Afterwards, Marc will provide an update on our financial results and milestone outlook. During the first half of 2024, we remain committed to advancing our maturing pipeline and are setting the stage for a transformative period ahead. Specifically, we continue to prepare for the data readout from the AL002 Phase 2 trial INVOKE-2 expected in Q4.

AL002 our novel TREM2 agonist aims to enhance TREM2 signaling and activate the healthy and beneficial role that microglia play in the setting of neurodegenerative diseases. This immuno-neurology approach leverages multiple mechanisms of healthy microglia to protect the brain against Alzheimer’s disease, potentially offering an efficacy advantage compared to current therapies that target individual misfolded proteins. AL002 is the most advanced TREM2 activating candidate in clinical development worldwide with potential a monotherapy or as an add-on therapy with anti-amyloids. Today, we will discuss the patient baseline characteristics reported for INVOKE-2 trial at the Alzheimer’s Association International Conference in July. These characteristics confirm a representative study population that enables testing of the effect of AL002 in early Alzheimer’s disease.

We will also delve into the multiple clinical trial imaging and biomarkers readouts for the INVOKE-2 trial, our common close design and statistical primary MMRM analysis and our long-term extension study, all of which were designed to strengthen the trial analysis. Additionally, Gary will share our thoughts on what the successful data readout look like. In February 2024, the FDA granted breakthrough therapy designation to latozinemab for the potential treatment of FTD with GRN limitations. You may recall that latozinemab is a monoclonal antibody that elevates the level of the immune regulatory protein progranulin by blocking sortilin. The breakthrough designation has provided the opportunity for increased interactions with the FDA on this program.

And now we have additional clarity on how key biomarkers may support our path to a potential regulatory submission. We will provide more details on this FDA feedback during today’s call. Looking ahead, we believe that we are on track for the pivotal Phase 3 data readouts from INFRONT-3 trial in late 2025, early 2026 and we plan to share more specifics soon. Enrollment continues in the PROGRESS-AD global Phase 2 clinical trial of AL101 for early Alzheimer’s disease with dosing initiated early this year. Like latozinemab, AL101 elevates progranulin level, but offers a distinct pharmacokinetics and pharmacodynamic profile suitable for broader indications. Furthermore, in June, we introduced Alector Brain Carrier, ABC, our proprietary blood-brain barrier technology platform.

ABC enhances the delivery of therapeutic agents with greater penetration and efficacy at lower doses with the goal of reducing costs and improving patient outcomes. The introduction of ABC represents a significant advancement in our capabilities to address these challenges of drug delivery in all degenerative diseases. To summarize, we continue advancing genetically validated first-in-class and best-in-class drug candidates for Alzheimer’s disease, front of temporal dementia and other indications. By targeting genetic pathways implicated in all degenerative diseases and combining innovative science with emerging technology, we continue to strive for a world where degenerative brain disorders are a relic of the past. At this time, I’ll turn the call over to Gary.

Gary Romano: Thank you, Arnon. I’m pleased to provide further insights into our later-stage clinical portfolio, focusing on our advancements with AL002 and our progranulin programs. I’ll begin with AL002. As a reminder, our ongoing INVOKE-2 Phase 2 trial, which was fully enrolled in September 2023 is a randomized, double-blind, placebo-controlled, common close study, evaluating up to 96 weeks of treatment with AL002 in 381 participants with early Alzheimer’s disease. This trial includes three doses of AL002, which demonstrated robust target engagement and increased microglial signaling in our Phase 1 study. At the Alzheimer’s Association International Conference, or AAIC last week, Alector presented participant baseline characteristics for INVOKE-2.

As Arnon mentioned, the baseline clinical assessments confirm enrollment of the intended population of participants with early Alzheimer’s disease. The clinical diagnosis and enrollment was mild cognitive impairment due to Alzheimer’s disease for 67% of participants and mild dementia due to Alzheimer’s disease for 33% of participants. Notably, participants with baseline amyloid assessments demonstrated a mean centiloid level of 100.1, aligning with expectations for early Alzheimer’s disease cohorts. This data marks an important milestone in our global Phase 2 trial, which aims to evaluate the safety and efficacy of AL002 while testing the hypothesis that this first-in-class TREM2 agonist may slow the progression of Alzheimer’s disease. We are on track for the INVOKE-2 data readout in the fourth quarter of 2024.

Today, I’d like to describe the trial’s outcome measures, our statistical analysis approach, our long-term extension study and the expected trial outcomes. The primary clinical outcome is the CDR Sum of Boxes. We are also collecting secondary clinical and functional outcome assessments, including the ADAS-Cog 13 and ADCS-ADL-MCI from which we will derive treatment effects on the integrated Alzheimer’s Rating Scale, or iADRS. This trial will also deliver a robust biomarker package, assessing target engagement, treatment effects on microglia and treatment effects on Alzheimer’s pathophysiology. Target engagement will be assessed by measuring treatment effects on CSF levels of soluble TREM2. You will recall that in our Phase 1 healthy volunteer study following single doses, we saw dose-dependent reductions in CSF soluble TREM2, including changes from baseline exceeding 50% at our highest doses.

Treatment effects on microglial signaling will be assessed by measuring levels of CSF1R, SPP1 and IL-1 RN, which reflects proliferation, survival and phagocytotic activity of microglia. As previously reported, we saw treatment effects on each of these pathways after single doses in our Phase 1 study. We are also exploring omics assessments of treatment-related changes in microglial subtypes. Treatment effects on Alzheimer’s pathophysiology will be assessed with CSF and plasma biomarkers, with A-beta and tau as well as both amyloid-PET and tau-PET. We will also have biomarkers of astrogliosis, neuroinflammation, synaptic health and neurodegeneration. The Phase 2 INVOKE-2 trial utilizes a common closed design in which participants remain in a double-blind study until the last participant completes 48 weeks of treatment.

Earlier enrolled participants continue in the double-blind study for a maximum of 96 weeks of treatment before they are invited to join our long-term extension study. We intend to use a proportional analysis approach or specifically proportional MMRM, which enables us to use all the data collected in this common closed design trial. This means we will include data from all participants out to 48 weeks and also include additional data provided by the participants who have – will have had follow-up for up to 96 weeks. Efficacy will be calculated as the average treatment effect observed across multiple post-baseline visits. This approach increases power, potentially enabling us to reach statistical significance at a smaller effect size. If our drug slows disease progression comparable to the treatment effects of the anti-amyloid antibodies, we may have served a significant treatment effect.

Our ongoing INVOKE-2 long-term extension study is currently underway for participants who completed the initial treatment period. This LTE study remains blinded to treatment assignment, allowing for an ongoing collection of meaningful clinical biomarker and safety data. Thus far, approximately 95% of eligible participants from INVOKE-2 have enrolled in the LTE study. In this LTE study, we are also assessing the effects of a modified dose titration on the severity of treatment-emergent MRI findings, resembling amyloid-related imaging abnormalities or ARIA. Participants who roll over from the placebo in the double-blind trial to active treatment in the LTE will begin titration at a lower dose than was used in the double-blind trial and will also have a slower dose titration schedule.

This is intended to explore the effects of starting at a lower dose and using slower titration on the observed treatment-related MRI findings that resemble ARIA. For context, in the INVOKE-2 double-blind trial, dosing started at 15 mg/kg and dose escalation occurred every four weeks during the first three months of the trial. Our hypothesis for the INVOKE-2 trial is that treatment with AL002 will increase TREM2 signaling, leading to therapeutic restoration of microglial functions that protect against neurodegenerative disease. This includes the clearance of misfolded proteins, such as amyloid, but we also expect AL002 to amplify the broader beneficial effects of healthy microglia on the brain such as maintenance of synaptic connections, support of astrocyte and oligodendrocyte function, repair and maintenance of the blood brain barrier and the vasculature and regulation of immune tolerance.

Thus, our expectation is that restoration of microglial function by AL002 will reduce the brain’s vulnerability to neurodegenerative disease and that the INVOKE-2 trial will demonstrate treatment-related slowing of Alzheimer’s disease progression as demonstrated by a combination of clinical, functional and biomarker readouts. With its broad and complementary mechanism of action, we expect AL002 to be effective as a standalone therapy and may also demonstrate additive or synergistic effects when used in combination with amyloid-targeted therapeutics. We also believe that treatment benefits of AL002 may manifest differently from what we have seen in trials of the anti-amyloid antibodies. For example, with regard to biomarker responses, lowering cerebral amyloid-PET signal to the 24 centiloid threshold, which for anti-amyloid antibodies appears to be a necessary condition for clinical efficacy may not be relevant to this mechanism of action that goes beyond amyloid clearance.

Additionally, optimal disease stages for intervention may be broader. Unlike therapeutics targeting amyloid or tau, we do not expect the beneficial effects of healthy microglia to be limited to specific pathophysiological stages of disease. And thus, AL002 may have potential to benefit patients ranging from preclinical Alzheimer’s disease through advanced dementia. Turning now to our progranulin programs. In a recent Type B interaction with the FDA, we and GSK received feedback on the potential future biologics license application for latozinemab. The FDA has indicated that it would consider the effects of latozinemab on plasma and cerebrospinal fluid progranulin levels as confirmatory evidence, supplementing the potential clinical effects of latozinemab, pending BLA review.

We also aligned with the agency on disease-relevant fluid and imaging biomarkers that may be considered as supportive evidence of clinical efficacy, also subject to BLA review. These include biomarkers of astrocyte function, neurodegeneration and brain atrophy. Based on the FDA feedback, we remain confident that the totality of evidence, including the primary clinical endpoint and biomarkers could provide a path to potential approval for latozinemab. Following these productive interactions with the FDA, we believe we are on track for the pivotal INFRONT-3 Phase 3 data readout in late 2025 or early 2026. In parallel, enrollment continues in the PROGRESS-AD global Phase 2 clinical trial of AL101 for early Alzheimer’s disease. We and GSK are co-developing AL101 for the potential treatment of more prevalent neurodegenerative diseases, including Alzheimer’s disease and Parkinson’s disease.

At AAIC, our partner GSK presented a poster highlighting data supporting the hypothesis that therapeutic increases of progranulin levels may be an effective treatment for Alzheimer’s disease. These findings demonstrate consistent causal associations between increased progranulin levels and reduced Alzheimer’s disease risk across the progranulin gene allelic spectrum, providing compelling genetic evidence for increasing progranulin levels as a potential therapeutic strategy to treat Alzheimer’s disease. As we advance these programs, we remain dedicated to harnessing our scientific and clinical expertise to drive forward transformative therapies for neurodegenerative diseases. At this time, I’ll turn it over to Sara for updates on our progress with the Alector Brain Carrier.

Sara Kenkare-Mitra: Thank you, Gary. In June, we held a virtual R&D event highlighting our Alector Brain Carrier, blood-brain barrier technology platform. At Alector, we have dedicated several years to developing our proprietary versatile Alector Brain Carrier technology known as ABC. We are leveraging the ABC platform as a vital tool in our preclinical pipeline and novel drug development. ABC enables us to expand our pipeline to include neurodegenerative diseases requiring enzyme or protein replacement. It enhances our novel antibody pipeline by improving brain distribution, potentially requiring lower doses and enabling subcutaneous delivery. Additionally, we are also leveraging our ABC technology in the development of second-generation drugs towards our pipeline and validated targets.

ABC has been validated with multiple therapeutic cargoes. Notably, we focused on two key transporting targets, transferrin receptor known as TfR and CD98 heavy chain. TfR, a well-known iron transport receptor swiftly delivers cargo to the endolysosomal system, while CD98 heavy chain antigrowth to amino acid transport complexes targets cargo primarily across the endothelial cell surface. Both receptors enabled effective delivery of functional cargoes, including antibodies and proteins to target its cells within the central nervous system. Having multiple receptor targets allows us to tailor brain uptake optimizing efficacy and safety. Our approach with ABC is distinguished by its versatility, tunability and translatability. Our ABC technology is versatile and can accommodate a wide range of cargoes from antibodies to nucleic acids, thus enhancing its application across neurodegenerative diseases.

Tunability is core to our technology, utilizing a diverse panel of binders with varying affinities to blood-brain barrier receptors to precisely match different cargoes, optimizing therapeutic efficacy while ensuring safety. Additionally, translatability from preclinical to clinical species is a key feature and can be important in accelerating our path to clinical trials, ultimately enabling efficient delivery of innovative treatments to patients. ABC’s capabilities underscore Alector’s commitment to advancing therapies for neurodegenerative diseases by overcoming challenges in drug delivery to the brain, positioning us at the forefront of neurodegenerative disease drug development. Looking ahead, we will continue to provide updates on our ABC programs as they progress, reinforcing our dedication to pioneering new frontiers in brain health.

Now I’ll turn the call over to Marc for an update on our financial results and milestone outlook.

Marc Grasso: Thank you, Sara. We summarized our second quarter 2024 financial results in the press release that we made available after the market closed today. First, I’ll highlight that we remain well funded to execute our strategic objectives. We ended the second quarter of 2024 with a strong cash position of $503.3 million. Our cash runway extends through 2026, demonstrating robust financial preparedness for future growth and financial strength through the completion of key milestones, including the AL002 INVOKE-2 Phase 2 data readout and the pivotal INFRONT-3 Phase 3 data readout for latozinemab, with the runway coverage extending approximately a year beyond the INFRONT-3 readout. Turning now to 2024 financial guidance.

We continue to anticipate collaboration revenue to be between $60 million and $70 million. We have tightened our total research and development guidance to be between $210 million and $220 million. We have reiterated our total general and administrative guidance to be between $60 million and $70 million. We are well capitalized for the robust cash position and remain focused on advancing our later stage and ABC portfolio. We look forward to providing additional updates as we progress our work. That concludes our prepared comments for today’s call. Operator, you may now open the line for questions.

Operator: [Operator Instructions] And our first question comes from Paul Matteis with Stifel.

Unidentified Analyst: Hi, there. This is Julian on for Paul. Thanks so much for taking our question. So a couple from me. On TREM2, do you mind just reminding everybody what proportion of data from participants out to 48 weeks and 96 weeks and somewhere in between you expect in this upcoming readout? And also do you plan on rolling over APOE4 homozygotes that were in the placebo group to your long-term extension study? And then also on latozinemab, can you just clarify what exactly does it mean that the FDA would consider plasma and CSF PGRN as confirmatory? I guess to me, it seems a little unusual as biomarkers – for a biomarker to be confirmatory evidence of clinical benefit. Usually, it’s predicting clinical benefit in the absence of clinical data. So any additional color would be really helpful there. Thank you.

Gary Romano: This is Gary. I can take that. So I think your first question was around TREM2, what is the – how many patients do we have at the different time points. So all of the patients, all the completers, which we expect to be around 250, will complete 48 weeks of treatment. And then we’ll have about half of those, we’ll have 72 weeks of treatment and about a third will have 96 weeks treatment. And I want to just remind you that our LTE is – remains blinded to original treatment assignment, which means that we’ll still be able to collect meaningful data on biomarkers and safety, but also on clinical outcomes, given the blindedness and the fact that – and that will be up so six months later, we’ll have a minimum of 72 weeks of data on all patients and then six months later, two years of data.

Your second question was about the LTE, I think, about rollover of APOE homozygotes. No, we are rolling over the placebo group, which is – which like the rest of the study at the current study population does not include APOE4 homozygotes anymore. They were – we stopped enrollment early in the study and discontinued them because we saw more severe MRI changes resembling ARIA in the APOE4 homozygotes. So they are not rolling over in the LTE. And I think your last question was about latozinemab, what does it mean to be confirmatory evidence in clinical benefit. It means that if we have a clinical – clinically – a positive result on the clinical – primary clinical outcome measure, which is the CDR – that the CDR FTD – FTLD NAC, it’s the – basically a CDR with two additional modules for behavior and language difficulties, which FTD patients have.

And what it means is that we discussed some specifics about some of the biomarkers, imaging and fluid biomarkers that we would use, including GFAP and NfL and region of interest volumetric – should you say, volumetric MRI, that they would be – they would – if we were to see effects on these biomarkers that would be added confirmatory evidence of the effect on the clinical outcome measure. It does not mean in this context that it would be – that the biomarkers would be surrogates for the clinical outcome measure. However, that said, I mean we are also fully cognizant that there are many similarities here in FTD to drugs like tofersen that was approved based on an accelerated approval based on some of the same biomarkers, NfL predominantly.

And likewise, in this study, we see these biomarkers are prognostic and FDA, we had a discussion with this about those similarities. And so if are for some reason, and we don’t expect this, but if – especially based on our Phase 2 data, which was very promising, we expect that if we did – if we were disappointed by the clinical outcome, but we saw directional effects, I mean, we think that a backup strategy could be an accelerated approval approach. We have not discussed that with FDA yet, but I think that their – we’re encouraged by their endorsement of the biomarkers that we suggested.

Unidentified Analyst: Got it. Make sense. Thanks. Appreciate it.

Operator: One moment for our next question. And our next question comes from Alec Stranahan with Bank of America.

Unidentified Analyst: Hi. This is Susan on for Alec. I had a question about INVOKE-2. How should we be thinking about patients enrolling in a long-term extension study for INVOKE-2 in terms of tolerability and efficacy?

Gary Romano: Yes. Thank you, Susan. So how do we think about patients enrolling in LTT around efficacy and safety? Well, first, I have to tell you that we’re very pleased by the fact that up to this point, 95% of patients that have been eligible to roll over and that’s most of the patients by far, have decided to do so and are now in the LTE. Some have actually completed the LTE. And in terms of efficacy, we will be – we don’t know. We are still blinded, and we haven’t looked at efficacy. We will include some of the LTE data that will be – have been collected up to that time in our sensitivity analysis as the time later this year when we lock the database and have a look at the data. With regard to safety, there really haven’t been any significant safety signals beyond the MRI signal that resembles ARIA, which we’ve described in a lot of detail. And also a small number of infusion reactions, which is not to be unexpected with the monoclonal antibody.

Arnon Rosenthal: Thank you, Susan. Operator, we’re ready for the next question.

Operator: One moment for our next question. And our next question comes from Jeffrey Hung with Morgan Stanley.

Michael Reid: Hi. This is Michael Reid on for Jeffrey. Thank you for taking our question. Going back to the baseline INVOKE data. So two-third had mild cognitive impairment and a third had mild dementia. But you also saw mean amyloid like PET centroids of around 100 a baseline. Are you able to say whether that differed between the two populations in terms of cognitive impairment versus dementia? And also it’s not a full capture of the total trial population. Is that something that will get resolved? Thanks. And I have a follow-up.

Gary Romano: Yes. So I can’t tell you – I don’t – we don’t have the data broken down by the MCI and mild AD regarding the centiloid levels. I don’t have that. We just looked at the aggregate centiloid levels. And we – let me see, did I miss your other question? I didn’t catch the question about full capture. I didn’t quite follow what you’re asking.

Michael Reid: Sorry about that. I just meant – like I thought it was like in the low – like mid-200s and the trial had enrolled more patients, like is mean amyloid PET at baseline something that would be captured through the whole population or just like the 244?

Gary Romano: Yes. So at the – this is baseline characteristics. So this was – what we reported out on was the number of patients that or the patients that had used amyloid PET for inclusion and therefore, had a baseline amyloid PET scan. So that would include everyone up to that point that – for which we had data which would be everyone, because they were fully enrolled. Yes. So that’s the – I hope this answers your question.

Michael Reid: Yes. No, that’s very helpful. And then just as a quick follow-on. Like what sort of – follow-up. What would you think is the expectations for centiloid reduction in INVOKE?

Gary Romano: Yes, that’s a good question. So since we see this MRI finding that resembles ARIA in every manner. We wouldn’t be surprised to lowering amyloid. We also wouldn’t be surprised given that the fact that this is a – we believe that AL002 will restore microglial function. And we know that microglia are involved in compacting and also clearing amyloid and other misfolded proteins in during – under regular conditions and also are involved in removal of amyloid after they get tagged by anti-amyloid antibodies. So it doesn’t surprise us that we would see that. In terms of the expectation, we don’t know yet and we haven’t yet looked. But I would tell you that we don’t see – I think this is a very important point.

We – this is really – this is a truly different mechanism than anti-amyloid antibodies. And it has – as we described in our presentation, we are – by restoring microglial function, we’re restoring many different downstream mechanisms by which microglia preserve brain health. So we don’t – this is really not intended to be just an amyloid-lowering agent. Therefore, if we do or do not reach the amyloid, the 24 centiloid level that seems to be a necessary condition for clinical efficacy for the anti-amyloid antibodies, that’s not going to bother us. And we’re not going to make a decision based on that because this really goes beyond amyloid clearance, this mechanism.

Michael Reid: Thank you so much. I really appreciate that.

Operator: One moment for our next question. And our next question comes from Pete Stavropoulos with Cantor Fitzgerald.

Unidentified Analyst: Hi. This is Samantha on the line for Pete. Thanks for taking our questions. Firstly, for TREM2, can you give us an idea of what to expect for the first data release next quarter? What’s the bar for moving this program forward into a later-stage study? Will it be biomarker driven? Or do you need to see a clear signal of clinical efficacy? And regarding safety monitoring, is it safe to assume that ARIA like observations have been minimized due to the protocol changes? Has there been any new KOL feedback on what might be driving these observations? And finally, regarding the ABC technology, could you describe the tissues or cell types where CD98 is expressed and outline any theoretical risks associated with targeting CD98? Thanks so much.

Gary Romano: Okay. Thanks. Good questions. Thanks, Samantha. So what to expect in terms of – what do you expect in terms of what data we’re going to report. We’re going to – we’ll have a press release and that press release will include, not only the typical top line primary clinical outcomes and safety, but we’re also going to include data on the relevant biomarkers. As I said, this is – we were making a decision based on a combination of clinical, functional and biomarker readouts and we have lots of biomarkers. So all of those that are relevant to making a decision, particularly the Alzheimer’s physiology biomarkers will be included, we’ll be reporting out on – we intend to report out on all of those at the same – with the press release, not just top line.

And what is the bar to advance? I just said it, right? It’s some combination there – and seeing consistency across those clinical and biomarker outcomes that – showing that we are slowing disease progression because that’s – at the end of the day, that’s what we’re out to do. So it’s not going to be about hitting a p-value on just clinical outcome measure that that’s – if we do or don’t, if we see directional effects there, consistent with biomarker directional effects showing slowing of disease progression for us, that’s a win. And that’s – we’ll be very excited to see that and advance the compound. You also asked about ARIA. Is it – do we think it’s minimized? Well, what we do know is that when we – after we dropped the APOE4, we then added MRI surveillance.

And MRI surveillance, actually, we were doing it every four weeks before each dose titration for the first three months and then less often after that. We know that likely increases the amount of ARIA you’re going to find because you’re looking every four weeks for radiographic ARIA, which is 90% of the ARIA. Lilly, by the way, reported at that in their donanemab Phase 3 program that date when they added ARIA surveillance, increased the ARIA surveillance, they saw more ARIA. Also they saw – in addition, they see more higher incidents, they also found that the severity was reduced. And we’ve also observed that, as I said, the incidence and severity of ARIA has actually come down for us in our study under the current population. Is it minimized?

Meaning is that as low as it can go? I don’t know. We don’t know that for sure, but I can tell you that in our long-term extension, one of the things that we’re exploring is whether starting at a lower dose and titrating more slowly akin to what they’ve been doing in the amyloid – anti-amyloid antibody trials could reduce the ARIA signal. So that – we hope to learn that as well in our long-term extension study. And what does this – what does the mechanism – yes. That was the mechanism, I’m sorry, well, I think the last question was talking about what about mechanism. Everyone we show this to says, this has to be related to amyloid clearance. We’re very – I’m kind of conservative. So I’ll wait till I see the data, but I think that’s a good bet.

And I think there’s a CD98 question for Sara.

Arnon Rosenthal: Yes, as to the – according to the human protein plus sort of CD98 express in endocrine tissues in the pancreas, in the kidney, in genitalia and a little bit in the skin. So yes, we will be looking if there’s any adverse effect in this tissue. In the brain, CD98 is expressed higher supporter in microglia and astrocyte and in lower levels in neurons outside of the endothelial cells, which enable – using it as a blood-and-barrier transport.

Unidentified Analyst: That’s helpful. Thank you so much.

Operator: One moment for our next question. And our next question comes from Yaron Werber with TD Cowen.

Unidentified Analyst: Hi. This is Brendan on for Yaron. Thanks for taking the question. Actually, just a quick one on the potential AbbVie opt-in payment. Can you maybe just remind us when – what the timing is to potentially book that if the data comes out in Q4 and was good, do you expect – would you expect to book that after the Phase 2 data maybe in Q1? Are there other gating factors there? And just kind of let us know how you would report that. And then obviously, just looking at the deeper pipeline, just wondering which of the trial programs you might expect to enter the clinics first, when you think that might happen? Thanks.

Gary Romano: Yes. Thanks for the questions, Brendan. So as it relates to the option payment with AbbVie, as you recall, that’s at their option, $250 million at the end of the Phase 2. So we’re aligned with them around the proof-of-concept study package and we plan to be sharing that package with them at the end of this year, Q4 of this year. And they have 90 days, both their acceptance of that package to decide if they’re opting in, so that would put the payment towards the end of Q1, early Q2 is our expectation currently. And then your second question around which of the programs in our earlier portfolio will be advancing and which is the most advanced. We have a number of disclosed programs and a number of undisclosed programs and we look forward to providing you updates around that portfolio as next year progresses in the coming years. We haven’t specifically made a statement at this time as to which one is advancing for us. Hopefully that helps Brendan.

Unidentified Analyst: Yes. Great. Thanks guys.

Operator: One moment for our next question. And our next question comes from Carter Gould with Barclays.

Carter Gould: Good afternoon. Thanks for taking the question. I guess, first off, I want to be clear on exactly what sort of being message coming out of that Type B meeting. It’s appreciating your affirmation of confidence in the primary endpoint, but it sounds like this is a contingency strategy in the context of a potentially equivocal data on the primary. Is that a fair characterization? And does this, in any way, represent an evolution of your regulatory strategy on that program? And then I guess just to follow up on coming out of INVOKE-2, it sounds like there’ll be a separation of data and path forward. So I guess, again, is that sort of a fair characterization that we shouldn’t expect any sort of commitment on moving the products forward necessarily when we get the data.

And I guess alongside that, as we think about AbbVie and their decision process, they did recently deprioritize or discontinue their A-beta program. How do you view that? And if there’s any read-through to 002? Thank you.

Marc Grasso: Thanks for the question, Carter. Maybe Gary, you take the first question. I’ll take the latter two.

Gary Romano: Yes, yes, sure. So, Carter, thanks for your question. No, this really is not a contingency strategy. We are committed and we’re optimistic that we can get a full approval based on the primary outcomes, secondary outcomes and the biomarkers. Our questions were really can we – are these the biomarkers? There’s a lot of biomarkers one could look at. We felt that the ones that we proposed were biomarkers that if we were to see effects, these are biomarkers that are prognostic to begin with. So if you see changes in NfL or GFAP even before there are symptoms, you see changes in volumetric MRI even before symptoms. So it’s a prognostic biomarker. If we don’t know yet whether it is a surrogate marker, but we would imagine that because you see these changes even in advance of clinical symptoms that changes in the trajectories of these biomarkers should support the clinical outcome.

This is a single study. It’s a rare disease. So it’s a relatively small study, it’s 100 patients. And so we’re always thinking and looking about how to devise our statistical analysis plan in a way that can best show that the drug is providing benefit. And we thought these are important questions to ask. If they didn’t think these biomarkers were relevant or good enough or whatever, then we would have maybe differently about our SAP, but we are very encouraged by this information. We really are committed to for a full approval based on the totality of the data.

Marc Grasso: Yes. And I think your second question, Carter, related – so we were answering the question the prior analyst was asking about the – I think the earlier pipeline on which programs would advance next, not referring to TREM2. That program, obviously, subject to AbbVie’s opt-in decision, that would be a component, but we’re looking forward to advancing that. We expect the next stage would be a Phase 3. If they opt in, they would be taking on that Phase 3 and we share 50-50 in the cost and also the profits as that program advances. And remind me your third question, Carter?

Carter Gould: Again, any read-through from AbbVie’s decision to deprioritize or discontinue their A-beta program sort of on some level, you could say that’s narrowing their Alzheimer’s portfolio? And do you see any read-through then to around their interest in 002? Thank you.

Marc Grasso: Yes. Yes. It’s really hard for us to speculate there. Maybe they didn’t see the differentiation they were looking for with that A-beta program relative to what else is out there. Again, we remind the broader mechanism and the complementary role that activation of microglia can play. So we don’t necessarily see a read-through there, but that’s our speculation. What we can say is we’re very aligned with AbbVie, including around, as I mentioned, and as Gary has highlighted, the Phase 2 data readout in the concept study package that’s associated with that.

Operator: One moment of our next question. And our next question comes from Tom Shrader with BTIG.

Tom Shrader: Good afternoon, thanks for taking the question. They’re on progress AD, the trial with 101. Have you seen or are you going to update us if you’re going to see – if you’ve seen the MRI signal characteristic of ARIA? It’s obviously interesting here, but at some level, doesn’t it derisk the entire progranulin program if you did see some ARIA?

Gary Romano: Yes, that’s a good question, Tom, as always. We have – we don’t have any risk – well, we – because this mechanism of action involved, we think involves microglia, we have built into the study MRI surveillance to look and see if we have ARIA. I can tell you that we haven’t seen any such signals thus far, study, it’s early days with that study. Would it derisk the program? You mean in the sense that it would somehow…

Tom Shrader: Say, extracellular sortilin does what it’s supposed to.

Gary Romano: Yes, I suppose so. I mean, I think – yes, I mean, I think in the same way that we think about it in AL002 it would be, in some ways, encouraging about biological activity. But so far, we just – we’re looking mostly just to make sure we don’t miss a safety signal that we need to keep an eye on. But we haven’t seen anything as yet.

Tom Shrader: And real quick, is increasing progranulin to high levels based on the biology that you guys are sold into, is that as broad an effect as increasing TREM2? It almost seems like a step backwards that you’re fixing the lysosome and hoping everything else follows rather than TREM2 forces everything. Is that a fair characterization?

Gary Romano: Arnon, do you want to – I’m happy to answer that, or if you – do you want to speak to it?

Arnon Rosenthal: Yes, it is a different mechanism, but progranulin also has a very broad range of activities. It is a lysosomal chaperone, as you said, it enhances lysosomal activity, which is a critical component in fighting misfolded protein, but it’s also a survival factor for multiple types of neurons. It sort of enhances sort of normal activity. So we think that, yes, these are different mechanisms and we think that because now the generation is sort of such a large unmet need, it’s worth testing multiple mechanisms. We don’t think that programming is less broad or is sort of – is similar to anti-beta antibody, for example, we think that progranulin is sufficiently broad to address multiple disease pathologies.

Tom Shrader: Okay, great. Thanks for the details.

Operator: One moment for our next question. Our next question comes from Myles Minter with William Blair & Company.

Sarah Schram: Hi, you’ve got Sarah on for Myles. Congrats on the progress. And thanks for taking our question. So can you just remind us whether all doses tested in INVOKE-2 would potentially be therapeutic? And as it relates to your powering assumptions, are you expecting to pool those treated patients or consider each dose arm individually? And second, now that we’ve seen the baseline characteristics in your view, how do these patients compare to those enrolled in other AD therapeutic trials we’ve seen regarding severity, stage of disease and biomarkers? And do you think the entire range of dosing, including 48 weeks will be long enough to see a measurable function decline in the placebo group to potentially separate from those treated patients?

Gary Romano: Well, they are great questions. Thank you. So do we think all doses are therapeutic? Well, yes, because in our Phase 1 study, we saw target engagement, so reductions in soluble TREM2. They were highest in the top two doses where we saw greater than 50%, but they were still robust in the low dose that we’re testing and even lower than that. So based on that, I think that that is – it would be therapeutic. We also saw increased – we saw increased microglial signaling across multiple pathways, IL-1 RN. I think we mentioned this in the call in CSF1R and SCP1 at all those doses. So yes, we do think that those are potentially therapeutic. In terms of the analysis, so we will look at each dose versus placebo, but we will also be pooling data.

And in fact, the top two doses are overlapping considerably in their PK. And so we will – that’s definitely part of our pre-specified analysis that we’ll be looking at definitely. How do the patients compare to the other anti-amyloid antibodies? Really right down the middle, I would say. I mean, the centiloid level is a bit higher than in a size of Leqembi, but it’s a little bit lower than what that they saw in donanemab, the same thing for the distribution of clinical diagnosis. And based on the data we had, it really looked right down the middle. So we were very pleased with that. And I think the last question was does the entire range of dose right, right. So I think you’re asking about would the duration of 48 weeks be enough. This is – one of the reasons for the common close design right here was that this is a novel mechanism.

And we can’t necessarily expect that the temporal dynamics and treatment effects of restoring microglial function will all happen at the same time, right? I mean if there are effects on clearing amyloid and synapses, we might expect those earlier. If there’s effects by restoring the maintenance functions of supporting oligodendrocytes and astrocytes in the blood-brain barrier, in the vasculature, immune tolerance, those could take – potentially could take longer. So we do think that 48 weeks, we should – we hope to see something at 48 weeks. We will have data out to 96. And that’s one of the reasons we and AbbVie really wanted to invest in the long-term extension to be blinded to treatment assignment so that we could get meaningful data even after – even after the double-blind, we’ll have to double – the study in the double-blind.

So I think some of those notifications could be early, but we think that the full effect of this mechanism may – it’s possible that it will take longer to see that. Hopefully, we’ll get to see that in those that we have data out to 72 weeks and even those out to 96. But if it’s emerging, we’ll – we have the study design to be able to capture that.

Sarah Schram: Make sense. Thank you.

Gary Romano: Thanks.

Operator: One moment for our next question. And our next question comes from Ananda Ghosh with H.C. Wainwright & Company.

Ananda Ghosh: Hi, thanks for taking question. I have a couple of questions. The first one is, of course, on the Type B meeting. So just curious, given FDA’s encouraging stand in the Hunter syndrome, where they might consider heparan sulfate as a surrogate biomarker, or if you look at ALS, the tofersen example, which you mentioned, what has been your like takeaway, like how open FDA might be to consider some of the biomarkers like progranulin itself as the surrogate biomarker for the PGRN program going forward?

Gary Romano: Yes. Thank you. I agree with you that there’s been a lot of – I think there’s been some regulatory flexibility. And certainly, when it comes to rare diseases that they seem to be more so – more flexibility in how they – and especially in considering biomarkers to be supportive or even enough for an approval and you gave some good examples. We’re encouraged by that. That doesn’t – but we are still – we still feel that we have a very good shot at a full approval with the more traditional approach. That said, if we’re disappointed somehow with what the clinical outcome measure here, which we think we are going to have a really good backup plan to – if we see biomarker changes as we expect to see. So I think we’re encouraged by that flexibility, but a full approval for us is it’s not debatable. It’s like it would be better for patients, better for us if we could get a full approval.

Ananda Ghosh: Got it. A follow-up question on the progranulin program is at the European ALS Conference, a lot of KOLs actually pointed out that and now it’s kind of well established in case of tofersen, you see the NFL drop much before than you see the clinical benefit coming from tofersen in SOD1-mutant patients. So for your progranulin program, have you thought about – thought like – is there a way to kind of to also track that where you see the clinical benefits kind of lags behind the drop in some of the key biomarkers or the way the biomarkers are progressing?

Gary Romano: Yes. Yes, I agree with you. And we – the same is true in FTD. You see changes in NFL before you see clinical signs and symptoms. That’s why in our study, we originally started out including patients who were asymptomatic, but we knew that we’re at risk because they had a progranulin loss of function mutation and they also had elevated NFL levels. We originally plan to include it in our primary analysis, but because they were – they’re hard to find and we had many fewer of them and because they had a lot of variability to the progression rates, we – last year, we went to FDA and EMA, and we proposed to focus on the symptomatic patients for the primary analysis, but we will still analyze that data in the presymptomatic patients as a sensitivity analysis.

So – and we’re very excited about that. We think if it’s going to work in symptomatic patients, it may work even better in the early patients in the presymptomatic patients. So – and yes, we may – we’ll see when we look at our data whether we see changes in NFL that precede the temporal dynamics of effects on those biomarkers versus the clinical outcomes.

Ananda Ghosh: Got it. And I just have two questions on the TREM2. The first one is both Biogen and obviously Lilly has done this, the low tau, high tau like analysis for their AD trials. So what have you – like do you have plans to kind of do a subgroup analysis later on where you are looking at low tau or high tau in – and to kind of figure out what – how the AL002 impacts in this kind of population? And the second is how fast the ramp-up might be for your titration schedule for AL002?

Gary Romano: Yes. So – okay. So about the tau, the question about really use tau terciles. Yes, we – that’s definitely part of our prespecified analysis. We’re going to – we will have p217 at every – in every patient. So we can do it by p217 levels. We’ve also have tau-PET in a smaller subset, but we’ll be doing it mostly based on plasma-p-tau markers. We are going to look at those terciles. That, of course, will tell us – would give us some indication of whether we are seeing – we are seeing differential effects across the disease spectrum in low-tau or mid-tau or high-tau patients. That said, we really don’t expect to see these differences as much with – this mechanism than you would with an anti-amyloid antibody, where there’s more of a defined window of the pathophysiology that may work the best.

The second question is about the ramp-up. So we – in our study, when we went to a titration, it was every 4 weeks was the increase in dose. And that’s why we – as I mentioned earlier, that we were putting in MRI surveillance. We’re slowing that titration down and starting at a lower dose in the patients that roll over in the LTE because we want to learn whether that could be mitigating for the ARIA.

Ananda Ghosh: Okay, thank you very much.

Arnon Rosenthal: Thanks, Ananda. Good questions. Operator, I think we have time for two more here.

Operator: One moment for our next question. Our next question is from Graig Suvannavejh with Mizuho Securities.

Graig Suvannavejh: Thank you very much for taking my question. And congrats on the progress. Earlier in your prepared remarks, you had mentioned I think the analytical methodology that you will apply to your INVOKE-2 trial. And I wanted to ask about how that particular methodology might compare with others in Alzheimer’s disease. It does seem as if you’ve taken an innovative approach here with the view that you’re hoping to increase the powering of the study, but someone who may not be as well-versed in that methodology. Could you just speak to the differences between how others have analyzed their Alzheimer’s trial? Thanks.

Gary Romano: Yes. Yes. So this proportional method that we’re using are proportional MMRM, as I mentioned, it allows us to look at – it allows you to – it’s really particularly helpful in the common close design where we have patients with different durations of treatment and we can use all of that data, as I outlined. This is a novel method, but it has been used before in Alzheimer’s trials and one of the DIAN studies it was used. And also, I believe that really used it as a sensitivity analysis in their Phase 2 and possibly one ASI, I don’t remember which study that was. So it is novel, but others have explored it. Yes, I think it’s – for us, we thought given the common close design and given that we were trying to make this really a biomarker-rich study, we would have a lot of different types of readouts.

We thought that this would be the best – really – and I should say AbbVie agreed around this design some years ago before the study started. So yes, I mean, we’ll also do sensitivity analysis with other more traditional approaches, but this is our primary outcome.

Arnon Rosenthal: Thanks for the question, Graig. Operator, I think we have time for one more.

Operator: Our next question then comes from Corinne Jenkins with Goldman Sachs.

Corinne Jenkins: Thanks, guys. Good afternoon. Maybe could you just talk a little bit – I think I understand, but if you could just square the comments you’ve made around containing the mechanism, is it related to amyloid clearance, but you don’t have to get the same degree of centiloid reduction that going to see clinical effect. And then maybe you could expand a little bit more on the cash runway guidance, particularly with respect to which activities around the ABC platform are going to be embedded within that time frame.

Gary Romano: Yes. So I’ll take the first one, Corinne. Thanks. Good question. Yes. So what I was referring to is that – so our hypothesis is that increasing TREM2 signaling triggers a number of other signaling pathways that allow for a proliferation of microglia, increased function and survival. And we think that this is going to shift the population of microglia. We know that with aging and with neurodegenerative disease, you have senescence of microglia. So by shifting the microglia to more healthy and active and functional microglia we’ll have all those beneficial effects that come – I won’t repeat that come from microglia, including amyloid clearance and clearance of misfolded proteins. And by the way, it’s interesting that we’re focused not on amyloid because of the potential ARIA-like signal.

But there’s lots of comorbidities that are usually seen with Alzheimer’s disease. So microglia are not selective for amyloid, they would clear TDP-43 and they would clear other alpha-synuclein and the like. So we think this is why we’re so excited about this mechanism. When I say it, it doesn’t need to reach the 24 centiloid level. I think for an anti-amyloid antibody, where that’s what it does. It lowers amyloid. It looks like there’s now plenty – lots of data showing that curve. You’ve seen the graphs, I’m sure we show that you need to get to a certain level before you start seeing clinical benefit. I mean the gantenerumab study is an example of one that didn’t quite get there. And in aducanumab, one of the studies didn’t get there, didn’t have clinical, the clinical data were less robust.

So it looks like you have to get down to this 24 centiloid level if that’s your mechanism you’re using. This mechanism goes beyond that. Yes, we might have amyloid clearance, but we think that all of these downstream mechanisms are at play. And so we’re not going to judge this mechanism of action based just on the amyloid clearance, the amount of amyloid clearance we see. I hope that – did that help or did that answer the question?

Corinne Jenkins: Yes. That was really helpful.

Arnon Rosenthal: Maybe I can add to this – I can add to this a little bit. There are data even in human that microglia in a TREM2-dependent manner can contain A-beta without removing it. They form a barrier between the A-beta plus and the surrounding neurons and they basically make the A-beta plus nerve – the A-beta can no longer injure the neurons. So you can get therapeutic benefit even on A-beta without removal of A-beta if you recruit microglia. And in addition, yes, as Gary said, the microglia responsible for replacement of damaged synaptic connections in Alzheimer’s disease, up to 50% of the synopsis can be damaged. They are responsible for the replacement of damaged myelin. There is significant myelin damage in Alzheimer’s disease. They are responsible for direct neural transmission without functional microglia, neural transmission is abnormal. So there are a lot of other activities that should translate to clinical benefit independent of A-beta pathology.

Marc Grasso: And just on the cash runway guidance, Corinne. So we reiterated that our runway is through 2026 and that’s a full two years beyond the expected TREM2 data readout end of this year and a full year beyond expected FTD Phase 3 readout end of next year and doesn’t assume any opt-in from AbbVie or other milestones or business development. So we think that’s a pretty healthy runway and a strong position as it relates to the Alector Brain Carrier portfolio. We’re going to provide more updates as that program progresses – as those programs progress. We haven’t said specifically what that would advance those programs through. But you could expect that that would be through INDs on programs.

Corinne Jenkins: Thank you.

Marc Grasso: Yes.

Operator: And this concludes the question-and-answer session. I would now like to turn it back to Marc for his closing remarks.

Marc Grasso: Thanks, everyone, for the thoughtful questions. Before we end the call, I’d just like to share, we will be participating in a number of upcoming conferences, including the Morgan Stanley Annual Global Healthcare Conference, September 5th, in New York; H.C. Wainwright’s Global Investment Conference on September 9th in New York; and Cantor’s Global Healthcare Conference on September 17th in New York. Thank you again for your time and attention today.

Operator: And thank you for your participation in today’s conference. This does conclude the program. You may now disconnect.